Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Neoplasms 10Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Ovarian Neoplasms 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 167fludarabine phosphate 102Cyclophosphamide 97Azacitidine 92Whole-Body Irradiation 78fludarabine 77Mycophenolic Acid 71Busulfan 68Tacrolimus 59Peripheral Blood Stem Cell Transplantation 55Decitabine 55Granulocyte Colony-Stimulating Factor 49Filgrastim 44Daunorubicin 44Cyclosporine 42Methotrexate 41Melphalan 41Etoposide 41Clofarabine 41Idarubicin 39Mitoxantrone 34Antilymphocyte Serum 34venetoclax 32thymoglobulin 23Thiotepa 23Stem Cell Transplantation 21Injections 16Gemtuzumab 16CPX-351 16Sirolimus 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid, Acute × BI 6727 × Clear all
NCT00804856 2023-10-03

Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

Boehringer Ingelheim

Phase 2 Completed
180 enrolled 44 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01721876 2023-02-08

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Boehringer Ingelheim

Phase 3 Completed
666 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01662505 2018-07-30

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Boehringer Ingelheim

Phase 1 Completed
19 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡